Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Thursday 02 November, 2006

XTL Biopharm Ltd

AGM Statement

                       ANNUAL GENERAL MEETING STATEMENT                        

NEW YORK, NEW YORK, November 2, 2006 - XTL Biopharmaceuticals Ltd. (NASDAQ:
XTLB; LSE: XTL; TASE: XTL) announced that at its adjourned Annual General
Meeting held yesterday, all the resolutions proposed to the shareholders were


XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of infectious diseases,
with a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule,
non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is
currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL
is also developing XTL-6865 - a combination of two monoclonal antibodies
against the hepatitis C virus - presently in Phase 1 clinical trials in
patients with chronic hepatitis C. XTL's hepatitis C pipeline also includes
several families of pre-clinical hepatitis C small molecule inhibitors.  XTL
also has an active in-licensing and acquisition program designed to identify
and acquire additional drug candidates. XTL is publicly traded on the NASDAQ,
London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Ron Bentsur, Chief Executive Officer
Tel: +1-(212)-531-5960



a d v e r t i s e m e n t